Clinical advances on danoprevir and triple therapy of danoprevir with Peg IFN and ribavirin regimen in treatment of chronic hepatitis C / 中华临床感染病杂志
Chinese Journal of Clinical Infectious Diseases
;
(6): 84-89, 2018.
Article
in Chinese
| WPRIM
| ID: wpr-709033
ABSTRACT
So far, thirty-seven clinical trials of danoprevir in treatment of chronic hepatitis C (CHC)have been completed globally,in which more than 2 600 patients were involved.The clinical trials among Chinese patients with genotype 1 CHC showed that the sustained virologic response(SVR)rate reached to 97.0% after twelve-week treatment of danoprevir combined with PR regimen(Peg IFN and ribavirin), and the safety was good.
Full text:
Available
Index:
WPRIM (Western Pacific)
Language:
Chinese
Journal:
Chinese Journal of Clinical Infectious Diseases
Year:
2018
Type:
Article
Similar
MEDLINE
...
LILACS
LIS